Market Cap | 235.81M | P/E | - | EPS this Y | 18.70% | Ern Qtrly Grth | - |
Income | -171.44M | Forward P/E | -1.58 | EPS next Y | 5.30% | 50D Avg Chg | -20.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
Dividend | N/A | Price/Book | 0.98 | EPS next 5Y | - | 52W High Chg | -63.00% |
Recommedations | 2.10 | Quick Ratio | 4.24 | Shares Outstanding | 52.67M | 52W Low Chg | 36.00% |
Insider Own | 1.92% | ROA | -49.01% | Shares Float | 24.10M | Beta | 1.02 |
Inst Own | 109.19% | ROE | -92.17% | Shares Shorted/Prior | 9.99M/9.28M | Price | 5.77 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 218,906 | Target Price | 9.33 |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 81,047 | Change | -3.19% |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
UBS | Buy | Aug 16, 24 |
HC Wainwright & Co. | Buy | Aug 13, 24 |
Cantor Fitzgerald | Overweight | Aug 12, 24 |
Stifel | Hold | Aug 9, 24 |
Stifel | Hold | Aug 1, 24 |
HC Wainwright & Co. | Buy | Aug 1, 24 |
HC Wainwright & Co. | Buy | Jun 10, 24 |
Cantor Fitzgerald | Overweight | May 29, 24 |
Cantor Fitzgerald | Overweight | Apr 12, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Pinto Shelly | VP, Finance and CAO VP, Finance and CAO | Dec 29 | Sell | 11.0699 | 482 | 5,336 | 62,097 | 01/03/23 |
Randolph Sophia | Chief Medical Office.. Chief Medical Officer | Dec 29 | Sell | 11.0704 | 1,617 | 17,901 | 270,253 | 01/03/23 |
GARCIA PETER S | Chief Financial Offi.. Chief Financial Officer | Dec 29 | Sell | 11.0701 | 893 | 9,886 | 53,723 | 01/03/23 |
Pons Jaume | President & CEO President & CEO | Dec 29 | Sell | 11.0701 | 3,232 | 35,779 | 539,746 | 01/03/23 |
Randolph Sophia | Chief Medical Office.. Chief Medical Officer | Dec 16 | Option | 3.6 | 46,474 | 167,306 | 271,870 | 12/20/22 |
GARCIA PETER S | Chief Financial Offi.. Chief Financial Officer | Feb 07 | Option | 4.45 | 15,000 | 66,750 | 24,483 | 02/08/22 |
Pons Jaume | President & CEO President & CEO | Feb 03 | Option | 1.45 | 24,154 | 35,023 | 468,978 | 02/07/22 |
Randolph Sophia | Chief Medical Office.. Chief Medical Officer | Dec 15 | Option | 1.45 | 23,852 | 34,585 | 188,396 | 12/16/21 |
Lettmann Jason | Director Director | Dec 13 | Sell | 27.91 | 325,377 | 9,081,272 | 285,956 | 12/15/21 |
LSV Associates, LLC | 10% Owner 10% Owner | Dec 13 | Sell | 27.91 | 48,390 | 1,350,565 | 285,956 | 12/15/21 |
Lettmann Jason | Director Director | Dec 08 | Sell | 32.17 | 145,637 | 4,685,142 | 291,758 | 12/10/21 |
LSV Associates, LLC | 10% Owner 10% Owner | Dec 08 | Sell | 32.17 | 145,637 | 4,685,142 | 291,758 | 12/10/21 |
Pons Jaume | President & CEO President & CEO | Oct 19 | Sell | 54.64 | 16,700 | 912,488 | 444,598 | 10/20/21 |
GARCIA PETER S | Chief Financial Offi.. Chief Financial Officer | Sep 17 | Sell | 79.63 | 12,771 | 1,016,955 | 9,331 | 09/17/21 |
GARCIA PETER S | Chief Financial Offi.. Chief Financial Officer | Sep 17 | Option | 4.08 | 12,771 | 52,106 | 20,676 | 09/17/21 |
Randolph Sophia | Chief Medical Office.. Chief Medical Officer | Sep 13 | Sell | 77.48 | 7,387 | 572,345 | 156,815 | 09/13/21 |
Pons Jaume | President & CEO President & CEO | Aug 20 | Sell | 63.06 | 16,700 | 1,053,102 | 477,998 | 08/20/21 |